Percutaneous thermoablation of small renal masses (T1a) in surgical candidate patients: oncologic outcomes.

Zangiacomo, Renato N.; Martins, Guilherme L. P.; Viana, Públio C. C.; Horvat, Natally; Arap, Marco A.; Nahas, William C.; Srougi, Miguel; Cerri, Giovanni G.; Menezes, Marcos R.

Objective: To evaluate the local tumour progression–free survival (LTPFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS) of healthy surgical candidates who underwent percutaneous thermoablation (TA) as a first-line therapy for small renal masses (T1a). Methods: The institutional review board approved this bi-institutional retrospective study of 85 consecutive surgical candidates with 97 biopsy-proven malignant renal masses (T1a) treated with percutaneous TA from 2008 to 2016. The LTPFS, MFS, CSS and OS rates were calculated using the Kaplan-Meier method. Descriptive analysis was also performed. Results: The median tumour size was 2.3 cm (range, 0.7–3.9 cm). The minimal and mean follow-up periods were 24 and 56 months, respectively. Local recurrence was detected in four patients (4.7%) at 8.5, 13.8, 58.0 and 64.0 months of follow-up and retreated successfully with percutaneous TA. No patient developed metastatic renal cell carcinoma, and none died due to renal oncologic complications. One patient died of heart attack. The 5-year LTPFS, OS, MFS and CSS rates were 93.0%, 98.4%, 100% and 100%, respectively. Only two patients (2.3%) had major complications (Clavien-Dindo grade > II), including ureteropelvic junction stenosis and urinary obstruction due to ureteral blood clots. Conclusions: Our study demonstrates that percutaneous TA is a feasible and effective first-line therapy for healthy surgical candidates with small renal masses (T1a). The 5-year LTPFS, OS, CSS and MFS rates were 93.0%, 98.4%, 100% and 100%, respectively, with a major complication rate of only 2.3%. Key Points: • Image-guided percutaneous thermoablation of small renal malignancies was effective in 95.3% of the healthy surgical candidates. • Major complications were detected in 2.3% of the patients. • The local tumour progression–free survival rate was 97.6% and 93.0% at 3 and 5 years, respectively.

SURVIVAL rate; MYOCARDIAL infarction; OVERALL survival; URETERIC obstruction; RENAL cell carcinoma

European Radiology, 2021, Vol 31, Issue 7, p5370

0938-7994

Academic Journal

10.1007/s00330-020-07496-z